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SV2A Syt II 
SYNAPTIC VESICLE 
SV2A PROTEIN 
Integral membrane protein, ubiquitously expressed and critical for  the CNS functioning. 
FUNCTION: Vesicle fusion and Ca2+ modulation. 
SV2A IN EPILEPSY 
Current antiepileptic drugs target the SV2A protein 
Homozygous SV2A KO mice suffer severe seizures at P7 
and die at P21 
SV2A levels decrease in patients suffering chronic epilepsy 
EPILEPSY 
 Common neurological disorder with around 25% of patients  suffering drug-resistant 
epilepsy. 
 SYMPTOMS:  Seizures, cognitive impairments, mood disorders. 
Is the SV2A protein implicated in the cognitive impairments detected in epilepsy? 
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 The SV2A decrease seems not to modify the hippocampal metabolism. 
 BUT, it produces spatial memory problems and anxiety-related features. 
 A sexual dimorphism is present in the symptomatology 
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